Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (81-90 of 238) with videos related to

Pageof 24
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|February 2, 2018
Confidence and Prediction Intervals for Pharmacometric ModelsAnne Kümmel, Peter L Bonate, Jasper Dingemanse, et al.
Sleep|September 4, 2021
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidemMike Ufer, Debra Kelsh, Kerri A Schoedel, et al.
Journal of Clinical Pharmacology|March 26, 2009
Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentanJasper Dingemanse, Atef Halabi, Paul L M van Giersbergen
British Journal of Clinical Pharmacology|June 6, 2002
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazolePaul L M van Giersbergen, Atef Halabi, Jasper Dingemanse
Pharmaceutical Research|December 12, 2019
Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor AntagonistsAnke-Katrin Volz, Jasper Dingemanse, Andreas Krause, et al.
British Journal of Clinical Pharmacology|April 23, 2002
Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjectsJasper Dingemanse, Martine Clozel, Paul L M van Giersbergen
The AAPS Journal|August 2, 2013
Population pharmacodynamic modeling of hyperglycemic clamp and meal tolerance tests in patients with type 2 diabetes mellitusYing Hong, Jasper Dingemanse, Patricia Sidharta, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 3, 2021
PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QTAndrea Henrich, Pierre-Eric Juif, Jasper Dingemanse, et al.
Drug Design, Development and Therapy|May 10, 2014
Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studiesJasper Dingemanse, Martine Gehin, Hans Gabriel Cruz, et al.
Journal of Cardiovascular Pharmacology|October 12, 2012
Pharmacokinetics, pharmacodynamics, and tolerability of ACT-077825, a new direct renin inhibitor after multiple-ascending doses in healthy subjectsLaurent B Nicolas, Marcelo Gutierrez, Christoph Binkert, et al.
Pageof 24

Showing results (81-90 of 238) with videos related to

Sort By:
Pageof 24
CPT: Pharmacometrics & Systems Pharmacology|February 2, 2018
Confidence and Prediction Intervals for Pharmacometric ModelsAnne Kümmel, Peter L Bonate, Jasper Dingemanse, et al.
Sleep|September 4, 2021
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidemMike Ufer, Debra Kelsh, Kerri A Schoedel, et al.
Journal of Clinical Pharmacology|March 26, 2009
Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentanJasper Dingemanse, Atef Halabi, Paul L M van Giersbergen
British Journal of Clinical Pharmacology|June 6, 2002
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazolePaul L M van Giersbergen, Atef Halabi, Jasper Dingemanse
Pharmaceutical Research|December 12, 2019
Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor AntagonistsAnke-Katrin Volz, Jasper Dingemanse, Andreas Krause, et al.
British Journal of Clinical Pharmacology|April 23, 2002
Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjectsJasper Dingemanse, Martine Clozel, Paul L M van Giersbergen
The AAPS Journal|August 2, 2013
Population pharmacodynamic modeling of hyperglycemic clamp and meal tolerance tests in patients with type 2 diabetes mellitusYing Hong, Jasper Dingemanse, Patricia Sidharta, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 3, 2021
PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QTAndrea Henrich, Pierre-Eric Juif, Jasper Dingemanse, et al.
Drug Design, Development and Therapy|May 10, 2014
Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studiesJasper Dingemanse, Martine Gehin, Hans Gabriel Cruz, et al.
Journal of Cardiovascular Pharmacology|October 12, 2012
Pharmacokinetics, pharmacodynamics, and tolerability of ACT-077825, a new direct renin inhibitor after multiple-ascending doses in healthy subjectsLaurent B Nicolas, Marcelo Gutierrez, Christoph Binkert, et al.
Pageof 24